CA2122717A1 - Hemoglobins as drug delivery agents - Google Patents
Hemoglobins as drug delivery agentsInfo
- Publication number
- CA2122717A1 CA2122717A1 CA002122717A CA2122717A CA2122717A1 CA 2122717 A1 CA2122717 A1 CA 2122717A1 CA 002122717 A CA002122717 A CA 002122717A CA 2122717 A CA2122717 A CA 2122717A CA 2122717 A1 CA2122717 A1 CA 2122717A1
- Authority
- CA
- Canada
- Prior art keywords
- hemoglobin
- hemoglobins
- drug delivery
- delivery agents
- drug
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
- C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/6445—Haemoglobin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Abstract
The invention relates to methods and compositions for delivering drugs to the body by binding them to hemoglobin. This technique stabilizes the drug and extends its half-life in the body. The drug may be chemically coupled to or adsorbed on the hemoglobin chain(s). Polypeptide therapeutics are ideally linked to an artificial hemoglobin via a cysteine located deep within a cleft in the hemoglobin molecule.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US78917791A | 1991-11-08 | 1991-11-08 | |
US789,179 | 1991-11-08 | ||
US789,177 | 1991-11-08 | ||
US07/789,179 US5545727A (en) | 1989-05-10 | 1991-11-08 | DNA encoding fused di-alpha globins and production of pseudotetrameric hemoglobin |
PCT/US1992/009713 WO1993008842A1 (en) | 1991-11-08 | 1992-11-06 | Hemoglobins as drug delivery agents |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2122717A1 true CA2122717A1 (en) | 1993-05-13 |
CA2122717C CA2122717C (en) | 2003-07-15 |
Family
ID=27120889
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002122717A Expired - Lifetime CA2122717C (en) | 1991-11-08 | 1992-11-06 | Hemoglobins as drug delivery agents |
Country Status (8)
Country | Link |
---|---|
US (2) | US5679777A (en) |
EP (1) | EP0611306B1 (en) |
JP (1) | JP3426599B2 (en) |
AT (1) | ATE168014T1 (en) |
AU (1) | AU665599B2 (en) |
CA (1) | CA2122717C (en) |
DE (1) | DE69226197T2 (en) |
WO (1) | WO1993008842A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017221185A1 (en) * | 2016-06-21 | 2017-12-28 | Therapure Biopharma Inc. | Hemoglobin-targeted drug delivery for the treatment of cancer |
Families Citing this family (75)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5478806A (en) * | 1989-11-22 | 1995-12-26 | Enzon, Inc. | Enhancement of antitumor therapy with hemoglobin-based conjugates |
AU665599B2 (en) * | 1991-11-08 | 1996-01-11 | Hemosol Inc. | Hemoglobins as drug delivery agents |
FR2686899B1 (en) | 1992-01-31 | 1995-09-01 | Rhone Poulenc Rorer Sa | NOVEL BIOLOGICALLY ACTIVE POLYPEPTIDES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM. |
WO1994022482A1 (en) * | 1993-03-26 | 1994-10-13 | Biorelease Technologies, Inc. | Compositions including heme-containing proteins and methods relating thereto |
US5665869A (en) * | 1993-11-15 | 1997-09-09 | Somatogen, Inc. | Method for the rapid removal of protoporphyrin from protoporphyrin IX-containing solutions of hemoglobin |
US6458762B1 (en) | 1994-03-28 | 2002-10-01 | Baxter International, Inc. | Therapeutic use of hemoglobin for preserving tissue viability and reducing restenosis |
US5670347A (en) | 1994-05-11 | 1997-09-23 | Amba Biosciences Llc | Peptide-mediated gene transfer |
GB9526733D0 (en) * | 1995-12-30 | 1996-02-28 | Delta Biotechnology Ltd | Fusion proteins |
EP1950298A3 (en) | 1997-05-02 | 2008-12-24 | Baxter Biotech Technology S.A.R.L. | Hemoglobin mutants with increased soluble expression and/or reduced nitric oxide scavenging |
US7378489B1 (en) | 1999-12-23 | 2008-05-27 | Protherics Medicines Development Limited | Angiotensin derivatives |
PT1001978E (en) * | 1997-06-24 | 2005-08-31 | Proteus Molecular Design | ANGIOTENSIN DERIVATIVES |
CA2236344A1 (en) * | 1998-04-30 | 1999-10-30 | Hemosol Inc. | Hemoglobin-haptoglobin complexes |
US20050059576A1 (en) * | 1998-04-30 | 2005-03-17 | Adamson J. Gordon | Targeted delivery of antiviral compounds through hemoglobin bioconjugates |
US6548540B2 (en) * | 1998-09-08 | 2003-04-15 | Charlotte-Mecklenburg Hospital Authority | Method of treating cancer using dithiocarbamate derivatives |
US6706759B1 (en) | 1998-09-08 | 2004-03-16 | Charlotte-Mecklenburg Hospital Authority | Method of treating cancer using dithiocarbamate derivatives |
US7816403B2 (en) * | 1998-09-08 | 2010-10-19 | University Of Utah Research Foundation | Method of inhibiting ATF/CREB and cancer cell growth and pharmaceutical compositions for same |
US6589987B2 (en) | 1998-09-08 | 2003-07-08 | Charlotte-Mecklenburg Hospital Authority | Method of treating cancer using tetraethyl thiuram disulfide |
US6706252B1 (en) | 1998-10-30 | 2004-03-16 | Rx/Ibr Corporation | Method of treating disease with radioisotopes conjugated to bioactive substances |
DE19926475A1 (en) | 1999-06-10 | 2000-12-14 | Ktb Tumorforschungs Gmbh | Carrier-drug conjugates |
US20060228364A1 (en) * | 1999-12-24 | 2006-10-12 | Genentech, Inc. | Serum albumin binding peptides for tumor targeting |
US20050287153A1 (en) * | 2002-06-28 | 2005-12-29 | Genentech, Inc. | Serum albumin binding peptides for tumor targeting |
CA2390691C (en) * | 1999-12-24 | 2016-05-10 | Genentech, Inc. | Methods and compositions for prolonging elimination half-times of bioactive compounds |
US20040001827A1 (en) * | 2002-06-28 | 2004-01-01 | Dennis Mark S. | Serum albumin binding peptides for tumor targeting |
JP2003522806A (en) | 2000-02-15 | 2003-07-29 | ジェンザイム、コーポレーション | Modification of biopolymers for improved drug delivery |
US6749865B2 (en) | 2000-02-15 | 2004-06-15 | Genzyme Corporation | Modification of biopolymers for improved drug delivery |
CA2405912A1 (en) * | 2000-04-12 | 2001-10-18 | Human Genome Sciences, Inc. | Albumin fusion proteins |
US6946134B1 (en) | 2000-04-12 | 2005-09-20 | Human Genome Sciences, Inc. | Albumin fusion proteins |
US20060084794A1 (en) * | 2001-04-12 | 2006-04-20 | Human Genome Sciences, Inc. | Albumin fusion proteins |
US20050244931A1 (en) * | 2001-04-12 | 2005-11-03 | Human Genome Sciences, Inc. | Albumin fusion proteins |
US7507413B2 (en) | 2001-04-12 | 2009-03-24 | Human Genome Sciences, Inc. | Albumin fusion proteins |
US20050054051A1 (en) * | 2001-04-12 | 2005-03-10 | Human Genome Sciences, Inc. | Albumin fusion proteins |
AU2002332041A1 (en) * | 2001-10-05 | 2003-04-22 | Human Genome Sciences, Inc. | Albumin fusion proteins |
US7214660B2 (en) | 2001-10-10 | 2007-05-08 | Neose Technologies, Inc. | Erythropoietin: remodeling and glycoconjugation of erythropoietin |
US7173003B2 (en) | 2001-10-10 | 2007-02-06 | Neose Technologies, Inc. | Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF |
GB0125793D0 (en) * | 2001-10-26 | 2001-12-19 | Panzeri Ezio | Method |
WO2005003296A2 (en) | 2003-01-22 | 2005-01-13 | Human Genome Sciences, Inc. | Albumin fusion proteins |
ES2545090T3 (en) | 2001-12-21 | 2015-09-08 | Human Genome Sciences, Inc. | Albumin and GCSF fusion proteins |
US20070026485A1 (en) | 2003-04-09 | 2007-02-01 | Neose Technologies, Inc. | Glycopegylation methods and proteins/peptides produced by the methods |
US7235639B2 (en) | 2003-04-23 | 2007-06-26 | Ezio Panzeri | Hemoglobin conjugates |
US9005625B2 (en) | 2003-07-25 | 2015-04-14 | Novo Nordisk A/S | Antibody toxin conjugates |
US20080305992A1 (en) | 2003-11-24 | 2008-12-11 | Neose Technologies, Inc. | Glycopegylated erythropoietin |
WO2006041641A2 (en) * | 2004-10-05 | 2006-04-20 | Genentech, Inc. | Therapeutic agents with decreased toxicity |
US20080176790A1 (en) | 2004-10-29 | 2008-07-24 | Defrees Shawn | Remodeling and Glycopegylation of Fibroblast Growth Factor (Fgf) |
EP1858543B1 (en) | 2005-01-10 | 2013-11-27 | BioGeneriX AG | Glycopegylated granulocyte colony stimulating factor |
US9187546B2 (en) | 2005-04-08 | 2015-11-17 | Novo Nordisk A/S | Compositions and methods for the preparation of protease resistant human growth hormone glycosylation mutants |
WO2006134173A2 (en) | 2005-06-17 | 2006-12-21 | Novo Nordisk Health Care Ag | Selective reduction and derivatization of engineered proteins comprising at least one non-native cysteine |
US7507842B2 (en) | 2005-08-12 | 2009-03-24 | Radiorx, Inc. | Cyclic nitro compounds, pharmaceutical compositions thereof and uses thereof |
US20070105755A1 (en) | 2005-10-26 | 2007-05-10 | Neose Technologies, Inc. | One pot desialylation and glycopegylation of therapeutic peptides |
US20090048440A1 (en) | 2005-11-03 | 2009-02-19 | Neose Technologies, Inc. | Nucleotide Sugar Purification Using Membranes |
DE102006011660A1 (en) * | 2006-03-12 | 2007-09-13 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Method for determining a doping density in a semiconductor sample |
CN101516388B (en) | 2006-07-21 | 2012-10-31 | 诺和诺德公司 | Glycosylation of peptides via O-linked glycosylation sequences |
US8969532B2 (en) | 2006-10-03 | 2015-03-03 | Novo Nordisk A/S | Methods for the purification of polypeptide conjugates comprising polyalkylene oxide using hydrophobic interaction chromatography |
US7504377B2 (en) * | 2006-10-23 | 2009-03-17 | Ikor, Inc. | Nitric oxide-blocked cross-linked tetrameric hemoglobin |
JP5492563B2 (en) | 2006-12-12 | 2014-05-14 | バイオレクシス ファーマシューティカル コーポレーション | Transferrin fusion protein library |
DK2144923T3 (en) | 2007-04-03 | 2013-05-13 | Biogenerix Ag | METHODS OF TREATMENT WITH USING GLYCOPEGYLATED G-CSF |
ES2551123T3 (en) | 2007-06-12 | 2015-11-16 | Ratiopharm Gmbh | Improved process for the production of nucleotide sugars |
JP2010536986A (en) * | 2007-08-20 | 2010-12-02 | エンゾン ファーマシューティカルズ,インコーポレーテッド | Polymer linker containing a pyridyl disulfide moiety |
CN101965200B (en) | 2008-02-27 | 2013-06-19 | 诺沃-诺迪斯克有限公司 | Conjugated factor VIII molecules |
US8436140B2 (en) * | 2008-06-02 | 2013-05-07 | Washington University | Natriuretic peptide-mediated imaging of atherosclerotic plaque |
EP2763667B1 (en) | 2011-10-07 | 2022-10-26 | EpicentRx, Inc. | Organonitro thioether compounds and medical uses thereof |
US20140308260A1 (en) * | 2011-10-07 | 2014-10-16 | Radiorx, Inc. | Methods and compositions comprising a nitrite-reductase promoter for treatment of medical disorders and preservation of blood products |
EP2872154B1 (en) * | 2012-07-11 | 2017-05-31 | Sangamo BioSciences, Inc. | Methods and compositions for delivery of biologics |
WO2014186301A1 (en) * | 2013-05-13 | 2014-11-20 | Vision Global Holdings Ltd. | Pharmaceutical composition comprising modified hemoglobin- based therapeutic agent for cancer targeting treatment and diagnostic imaging |
US9814759B2 (en) * | 2014-07-02 | 2017-11-14 | Cheer Global Ltd. | Pharmaceutical composition comprising recombinant hemoglobin protein or subunit-based therapeutic agent for cancer targeting treatment |
PL412787A1 (en) | 2015-06-22 | 2017-01-02 | Magdalena Król | Macrophage-based aimed system for delivery of ferritin related compounds |
US10342778B1 (en) | 2015-10-20 | 2019-07-09 | Epicentrx, Inc. | Treatment of brain metastases using organonitro compound combination therapy |
US9987270B1 (en) | 2015-10-29 | 2018-06-05 | Epicentrix, Inc. | Treatment of gliomas using organonitro compound combination therapy |
ES2880482T3 (en) | 2016-01-11 | 2021-11-24 | Epicentrx Inc | Compositions and methods for intravenous administration of 2-bromo-1- (3,3-dinitroazetidin-1-yl) ethanone |
WO2017197499A1 (en) * | 2016-04-25 | 2017-11-23 | The Governing Council Of The University Of Toronto | Stabilized hemoglobin-avidin assembly and method of preparation |
EA201990949A1 (en) | 2016-10-14 | 2019-10-31 | SULPHOXIALKYL ORGANIC NITRO COMPOUNDS AND RELATED COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR USE IN MEDICINE | |
SG11201907358RA (en) * | 2017-02-08 | 2019-09-27 | Hkl Medical Llc | Intrasite administration and dosing methods and pharmaceuticals for use therein |
SG11201914046WA (en) | 2017-07-07 | 2020-01-30 | Epicentrx Inc | Compositions for parenteral administration of therapeutic agents |
WO2019164593A2 (en) | 2018-01-08 | 2019-08-29 | Epicentrx, Inc. | Methods and compositions utilizing rrx-001 combination therapy for radioprotection |
EP3650046A1 (en) | 2018-11-08 | 2020-05-13 | Cellis AG | Mesenchymal stem cell based targeted active ingredient delivery system |
WO2024056413A1 (en) | 2022-09-13 | 2024-03-21 | Cellis Ag | Isolated targeted delivery system for the treatment of glioma |
Family Cites Families (75)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3934008A (en) * | 1968-08-23 | 1976-01-20 | Ciba-Geigy Corporation | N-acyl and desamino human calcitonin and analogs thereof |
US3980764A (en) * | 1973-11-05 | 1976-09-14 | Curtis Nuclear Corporation | Polymeric competitive protein binding adsorbents for radioassey |
US4042677A (en) * | 1974-08-29 | 1977-08-16 | Union Carbide Corporation | Technetium-99m labeled radiodiagnostic agents and method of preparation |
DE2449885C3 (en) * | 1974-10-21 | 1980-04-30 | Biotest-Serum-Institut Gmbh, 6000 Frankfurt | Process for the production of chemically modified, long-life hemoglobin preparations as well as the modified hemoglobin preparation produced by this process |
US4001200A (en) * | 1975-02-27 | 1977-01-04 | Alza Corporation | Novel polymerized, cross-linked, stromal-free hemoglobin |
US4061736A (en) * | 1975-02-02 | 1977-12-06 | Alza Corporation | Pharmaceutically acceptable intramolecularly cross-linked, stromal-free hemoglobin |
US4001401A (en) * | 1975-02-02 | 1977-01-04 | Alza Corporation | Blood substitute and blood plasma expander comprising polyhemoglobin |
US4053590A (en) * | 1975-02-27 | 1977-10-11 | Alza Corporation | Compositions of matter comprising macromolecular hemoglobin |
DE2740053A1 (en) * | 1977-09-06 | 1979-05-03 | Klaus Prof Dr Med Gersonde | USE OF ALLOSTERIC EFFECTORS WITH THE LIPID VESICLES WITH AN IRREVERSIBLE INCORPORATION FOR THE IMPROVED O DEEP 2 DISCHARGE OF THE HAEMOGLOBIN IN ERYTHROCYTES |
DE2843963A1 (en) * | 1978-10-09 | 1980-04-24 | Merck Patent Gmbh | BODY-RESORBABLE SHAPED MATERIAL BASED ON COLLAGEN AND THEIR USE IN MEDICINE |
JPS6023084B2 (en) * | 1979-07-11 | 1985-06-05 | 味の素株式会社 | blood substitute |
US4769326A (en) * | 1980-02-29 | 1988-09-06 | The Regents Of The University Of California | Expression linkers |
US4338397A (en) * | 1980-04-11 | 1982-07-06 | President And Fellows Of Harvard College | Mature protein synthesis |
DE3171463D1 (en) * | 1980-04-28 | 1985-08-29 | Nat Res Dev | Improvements in or relating to porous glass |
JPS5716815A (en) * | 1980-07-02 | 1982-01-28 | Ajinomoto Co Inc | Oxygen transporting agent for artificial blood |
US4551433A (en) * | 1981-05-18 | 1985-11-05 | Genentech, Inc. | Microbial hybrid promoters |
US4374932A (en) * | 1981-06-08 | 1983-02-22 | G. D. Searle & Co. | 5-ASA Drug delivery system |
JPS57206622A (en) * | 1981-06-10 | 1982-12-18 | Ajinomoto Co Inc | Blood substitute |
US4474893A (en) * | 1981-07-01 | 1984-10-02 | The University of Texas System Cancer Center | Recombinant monoclonal antibodies |
US4500507A (en) * | 1981-10-30 | 1985-02-19 | Wong Dennis W | Diagnostic composition for radiologic imaging of neoplasms in the body and method of preparation |
DE3144705C2 (en) * | 1981-11-11 | 1983-12-08 | Biotest-Serum-Institut Gmbh, 6000 Frankfurt | Process for the production of a storage-stable, cross-linked hemoglobin preparation with high oxygen transport capacity, as well as the hemoglobin preparation produced by this process |
US4540564A (en) * | 1982-05-18 | 1985-09-10 | University Of Florida | Brain-specific drug delivery |
IT1153000B (en) * | 1982-07-01 | 1987-01-14 | Resem Spa | WATER DISPERSIONS OF POLYURETHANES FROM OLIGOURETANS WITH UNSATURATED TERMINAL GROUPS |
US4599197A (en) * | 1982-12-22 | 1986-07-08 | Genentech, Inc. | Purification and activity assurance of precipitated heterologous proteins |
US4511503A (en) * | 1982-12-22 | 1985-04-16 | Genentech, Inc. | Purification and activity assurance of precipitated heterologous proteins |
US4620948A (en) * | 1982-12-22 | 1986-11-04 | Genentech, Inc. | Purification and activity assurance of precipitated heterologous proteins |
US4512922A (en) * | 1982-12-22 | 1985-04-23 | Genentech, Inc. | Purification and activity assurance of precipitated heterologous proteins |
US4713339A (en) * | 1983-01-19 | 1987-12-15 | Genentech, Inc. | Polycistronic expression vector construction |
US4529719A (en) * | 1983-05-04 | 1985-07-16 | Tye Ross W | Modified crosslinked stroma-free tetrameric hemoglobin |
GB8328917D0 (en) * | 1983-10-28 | 1983-11-30 | Fisons Plc | Blood substitute |
US4840896A (en) * | 1983-11-02 | 1989-06-20 | Integrated Genetics, Inc. | Heteropolymeric protein |
US4738952A (en) * | 1984-04-27 | 1988-04-19 | Synthetic Blood Corporation | Substitute for human blood and a method of making the same |
GB8412517D0 (en) * | 1984-05-16 | 1984-06-20 | Nagai K | Recombinant fusion proteins |
US4598064A (en) * | 1984-06-27 | 1986-07-01 | University Of Iowa Research Foundation | Alpha-alpha cross-linked hemoglobins |
US4600531A (en) * | 1984-06-27 | 1986-07-15 | University Of Iowa Research Foundation | Production of alpha-alpha cross-linked hemoglobins in high yield |
US4625014A (en) * | 1984-07-10 | 1986-11-25 | Dana-Farber Cancer Institute, Inc. | Cell-delivery agent |
US4542225A (en) * | 1984-08-29 | 1985-09-17 | Dana-Farber Cancer Institute, Inc. | Acid-cleavable compound |
JPS6191131A (en) * | 1984-10-09 | 1986-05-09 | Chugai Pharmaceut Co Ltd | Method and composition for preventing adsorption of pharmaceutical |
US4774180A (en) * | 1986-02-26 | 1988-09-27 | Massachusetts Institute Of Technology | Construction and application of polyproteins |
WO1986004217A2 (en) * | 1985-01-18 | 1986-07-31 | Kailash Kumar Gauri | Protein hydrolysates, production process and drugs containing th em |
US4584130A (en) * | 1985-03-29 | 1986-04-22 | University Of Maryland | Intramolecularly cross-linked hemoglobin and method of preparation |
DE3515252C2 (en) * | 1985-04-27 | 1994-02-24 | Roehm Gmbh | Process for the immobilization of dissolved proteins |
SE456136B (en) * | 1985-06-17 | 1988-09-12 | Oncholab Ab | PROCEDURE FOR THE PREPARATION OF A LIPOPHILIC BIOLOGY ACTIVE SUBSTANCE BASED BEARING BASIS OF RECONSTITUTED LDL (Layer Density Lipoprotein) |
DE3675588D1 (en) * | 1985-06-19 | 1990-12-20 | Ajinomoto Kk | HAEMOGLOBIN TIED TO A POLY (ALKENYLENE OXIDE). |
EP0238645A1 (en) * | 1985-10-03 | 1987-09-30 | Biotechnology Research Partners, Ltd. | Novel lipoprotein-based drug-delivery systems |
US4783529A (en) * | 1985-12-03 | 1988-11-08 | Research Corporation Technologies | Rapid synthesis of radiolabeled porphyrin complexes for medical application |
US4849142A (en) * | 1986-01-03 | 1989-07-18 | Jupiter Technologies, Inc. | Superplastic forging of zirconia ceramics |
US4826811A (en) * | 1986-06-20 | 1989-05-02 | Northfield Laboratories, Inc. | Acellular red blood cell substitute |
US4704692A (en) * | 1986-09-02 | 1987-11-03 | Ladner Robert C | Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides |
US4730936A (en) * | 1986-10-10 | 1988-03-15 | The United States Of America As Represented By The Secretary Of The Air Force | Gas driven system for preparing large volumes of non-oxidized, pyridoxylated, polymerized stroma-free hemoglobin solution for use as a blood substitute |
DE3636590A1 (en) * | 1986-10-28 | 1988-05-26 | Braun Melsungen Ag | BLOOD REPLACEMENT |
DE3702105A1 (en) * | 1987-01-24 | 1988-08-04 | Bayer Ag | PARENTERAL SOLUTION |
WO1988006601A1 (en) * | 1987-03-02 | 1988-09-07 | Genex Corporation | Gene repressors |
GB8711614D0 (en) | 1987-05-16 | 1987-06-24 | Medical Res Council | Proteins |
US5069936A (en) * | 1987-06-25 | 1991-12-03 | Yen Richard C K | Manufacturing protein microspheres |
US5049493A (en) * | 1987-10-23 | 1991-09-17 | California Institute Of Technology | Enhancement of cell growth by expression of a cloned hemoglobin gene |
EP0319206A3 (en) * | 1987-11-30 | 1990-04-18 | Berlex Laboratories, Inc. | Gene amplification |
JP2561122B2 (en) * | 1988-04-13 | 1996-12-04 | 寳酒造株式会社 | Functional polypeptide |
ES2096557T3 (en) * | 1988-04-14 | 1997-03-16 | Incyte Pharma Inc | LECTINAS 14-BETA-GAL DE MAMIFEROS. |
US5137819A (en) * | 1988-07-08 | 1992-08-11 | University Of British Columbia | Cellulose binding fusion proteins for immobilization and purification of polypeptides |
IL87708A (en) * | 1988-09-08 | 1994-04-12 | Technion Inst For Research And | Hemoglobin-based blood substitute possessing a colloid oncotic pressure substantially similar to human blood and method for the preparation thereof |
IE63847B1 (en) * | 1989-05-05 | 1995-06-14 | Res Dev Foundation | A novel antibody delivery system for biological response modifiers |
US5545727A (en) * | 1989-05-10 | 1996-08-13 | Somatogen, Inc. | DNA encoding fused di-alpha globins and production of pseudotetrameric hemoglobin |
US5599907A (en) * | 1989-05-10 | 1997-02-04 | Somatogen, Inc. | Production and use of multimeric hemoglobins |
DE69034091T2 (en) * | 1989-05-10 | 2004-04-22 | Baxter Biotech Technology S.A.R.L. | Production of hemoglobin and analogues thereof in non-erythrocyte cells |
NL8901174A (en) * | 1989-05-10 | 1990-12-03 | Het Hoofd Van De Afdeling Mili | HEMOGLOBINE PREPARATION AND USE THEREOF. |
FR2650598B1 (en) * | 1989-08-03 | 1994-06-03 | Rhone Poulenc Sante | DERIVATIVES OF ALBUMIN WITH THERAPEUTIC FUNCTION |
US5173426A (en) * | 1989-10-06 | 1992-12-22 | Yale University | DNAs encoding genetically engineered low oxygen affinity mutants of human hemoglobin |
JP2829397B2 (en) * | 1989-10-09 | 1998-11-25 | 寳酒造株式会社 | Fibrin binding active polypeptide |
US5234903A (en) * | 1989-11-22 | 1993-08-10 | Enzon, Inc. | Chemically modified hemoglobin as an effective, stable non-immunogenic red blood cell substitute |
DE3938953A1 (en) * | 1989-11-24 | 1991-05-29 | Max Planck Gesellschaft | CLONING AND EXPRESSION OF THE HT7 SPECIFIC PROTEIN FOR BLOOD BRAIN BARRIERS |
DK608589D0 (en) * | 1989-12-01 | 1989-12-01 | Holm Arne | CHEMICAL PROCEDURE |
WO1991009134A1 (en) * | 1989-12-15 | 1991-06-27 | Takeda Chemical Industries, Ltd. | Biospecific antibody to cancer cell and enzyme with prodrug-activating characteristics |
US5250665A (en) * | 1991-05-31 | 1993-10-05 | The University Of Toronto Innovations Foundation | Specifically β-β cross-linked hemoglobins and method of preparation |
AU665599B2 (en) * | 1991-11-08 | 1996-01-11 | Hemosol Inc. | Hemoglobins as drug delivery agents |
-
1992
- 1992-11-06 AU AU31324/93A patent/AU665599B2/en not_active Ceased
- 1992-11-06 AT AT92925154T patent/ATE168014T1/en not_active IP Right Cessation
- 1992-11-06 EP EP92925154A patent/EP0611306B1/en not_active Expired - Lifetime
- 1992-11-06 DE DE69226197T patent/DE69226197T2/en not_active Expired - Lifetime
- 1992-11-06 US US08/240,711 patent/US5679777A/en not_active Expired - Lifetime
- 1992-11-06 CA CA002122717A patent/CA2122717C/en not_active Expired - Lifetime
- 1992-11-06 WO PCT/US1992/009713 patent/WO1993008842A1/en active IP Right Grant
- 1992-11-06 JP JP50878193A patent/JP3426599B2/en not_active Expired - Lifetime
-
1995
- 1995-06-01 US US08/457,753 patent/US5759517A/en not_active Expired - Lifetime
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017221185A1 (en) * | 2016-06-21 | 2017-12-28 | Therapure Biopharma Inc. | Hemoglobin-targeted drug delivery for the treatment of cancer |
Also Published As
Publication number | Publication date |
---|---|
WO1993008842A1 (en) | 1993-05-13 |
US5759517A (en) | 1998-06-02 |
AU3132493A (en) | 1993-06-07 |
EP0611306A1 (en) | 1994-08-24 |
JP3426599B2 (en) | 2003-07-14 |
AU665599B2 (en) | 1996-01-11 |
ATE168014T1 (en) | 1998-07-15 |
CA2122717C (en) | 2003-07-15 |
DE69226197T2 (en) | 1999-02-11 |
EP0611306B1 (en) | 1998-07-08 |
US5679777A (en) | 1997-10-21 |
DE69226197D1 (en) | 1998-08-13 |
JPH07500840A (en) | 1995-01-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2122717A1 (en) | Hemoglobins as drug delivery agents | |
AU2173988A (en) | Stabilised human protein preparations | |
FI911319A0 (en) | POLYPEPTIDDERIVAT. | |
HK28097A (en) | Cyclosporin-containing pharmaceutical composition | |
ATE493998T1 (en) | PHARMACEUTICAL COMPOSITION CONTAINING AN EXENDIN-4 PEPTIDE | |
CA2138161A1 (en) | Glucagon-like peptide and insulinotropin derivatives | |
CY2052B1 (en) | Polymyxin conjugates | |
IL103383A0 (en) | Pharmaceutical compositions containing glutamine and methods for the use thereof | |
EP0612530A3 (en) | Pharmaceutical preparations containing tumor cytotoxic factor. | |
IL103676A0 (en) | Pharmaceutical compositions containing hemoglobins as drug delivery agents and methods for the preparation thereof | |
WO1994015962A3 (en) | Derivatized calcitonins |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
MKEX | Expiry |